• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Synta stops melanoma drug trials due to serious safety risks

Article

National report - Synta Pharmaceuticals has stopped drug trials for a melanoma drug due to serious safety issues, Forbes.com reports.

National report

- Synta Pharmaceuticals has stopped drug trials for a melanoma drug due to serious safety issues, Forbes.com reports.

The drug, called elesclomol, was supposed to work by increasing oxidative stress, which would cause cancer cells to self-destruct. However, during the trials there was a higher death rate among patients taking the experimental drug, according to Forbes.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.